This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

Our Compounds

Boehringer Ingelheim is taking on cancer through a dedicated commitment to delivering first-in-class cancer cell-directed therapies, innovative immuno-oncology strategies and smart combination approaches.

Filter by:
Phase I Phase II Phase III
Cancer cell-directed and immuno-oncology therapies

MEK inhibitor (in preparation)

DLL3-CD3 bispecific antibody (in preparation)

VSV-GP oncolytic virus platform (in preparation)

Combination Approaches

*Afatinib is approved in more than 80 markets, including the EU, Japan, Taiwan and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please see here. Registration conditions differ internationally; please refer to locally approved prescribing information.

**Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information please click here. Nintedanib is not approved in other oncology indications.

Xentuzumab, BI 836880, BI 894999, BI 754091, BI754111, BI 891065, BI 907828, BI 905677, BI 905681, BI 765063, BI 1361849, BI 1701963, KISIMA™ cancer vaccine (ATP-128), STING agonist, BI 905711, MEK inhibitor, DLL3/CD3 bispecific antibody and VSV-GP oncolytic virus platform are investigational compounds and have not been approved. Their safety and efficacy have not been established.

Ang2, angiopoietin 2; BET, bromodomain and extra terminal motif; CD, cluster of differentiation; CDH17, cell anchor cadherin 17; CRC, colorectal cancer; DLL3, Delta-like 3; EGFR, epidermal growth factor receptor; ErbB, epidermal growth factor receptor tyrosine kinase family receptor; FGFR, fibroblast growth factor receptor; GP, glycoprotein; HER2, human epidermal growth factor receptor 2; IGF, insulin-like growth factor; KRAS, Kirsten rat sarcoma; LAG-3, lymphocyte activation gene 3 protein; LRP5/6, lipoprotein receptor-related protein 5/6; MEK, mitogen-activated extracellular signal regulated kinase; MDM2, murine double minute 2 protein; mRNA, messenger ribonucleic acid; NSCLC: non-small-cell lung carcinoma; PD-1, programmed cell death protein-1; PDGFR, platelet-derived growth factor receptor; SIRPα, signal-regulatory protein alpha; SMAC, second mitochondria-derived activator of caspase; SOS1, Son of sevenless homolog 1; STING, small molecule agonist of the stimulator of interferon genes; TRAILR2, tumour necrosis factor-related apoptosis-inducing ligand receptor 2; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor; VSV, vesicular stomatitis virus.


© 2020 Boehringer Ingelheim International GmbH. All rights reserved.

Page last updated: March 2020



Prescribing Information: GIOTRIF®. (Accessed: March 2020).


Prescribing Information: VARGATEF®. (Accessed: March 2020).

3 NCT03099174. (Accessed: March 2020).

4 NCT02123823. (Accessed: March 2020).

5 NCT03659136. (Accessed: March 2020).

6 NCT03468426. (Accessed: March 2020).

7 NCT02952248. (Accessed: March 2020).

8 NCT03156114. (Accessed: November 2019).

9 NCT03780725. (Accessed: November 2019).

10 NCT03013998. (Accessed: November 2019).

11 NCT03166631. (Accessed: November 2019).

12 NCT03964233. (Accessed: November 2019).

13 NCT02674152. (Accessed: November 2019).

14 NCT02689505. (Accessed: November 2019).

15 NCT03468426. (Accessed: November 2019).

16 NCT02516553. (Accessed: November 2019).

17 NCT03449381. (Accessed: November 2019).

18 NCT03604445. (Accessed: November 2019).

19 NCT03990233.  (Accessed: November 2019).

20 NCT04111458. (Accessed: November 2019).

21 NCT03164772. (Accessed: November 2019).

22 NCT04046445. (Accessed: December 2019).

23 NCT03697304. (Accessed: November 2019).